AI Drug Developer Basecamp Valued at $800 Million After $140 Million Funding Round
Basecamp Research, an AI-driven drug developer based in London, raised $140 million in a Series C funding round led by S32, valuing the company at $800 million. Investors include Nvidia, Anthropic's Anthology Fund, and the Rockefeller Foundation. The company plans to use the funds to advance its EDEN biological foundation models and develop AI-designed therapies targeting cancer and autoimmune diseases. Basecamp reported strong preclinical results but did not specify clinical trial timelines. Former Biogen executive Richard Pearce joined as chief business officer to enhance pharmaceutical partnerships.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 49/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 23 Sept, 01:17 pm. Other outlets followed.